Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. (13th April 2020)

• Record Type: Journal Article
• Authors: Chaillon, Antoine; Wynn, Adriane; Kushner, Tatyana; Reau, Nancy; Martin, Natasha K
• Is Part Of: Clinical infectious diseases. Volume 73:Number 9(2021)
• Page Start: e3355
• Page End: e3357
• Publication Date: 2020-04-13
• Subjects: testing -- hepatitis C virus -- economic -- treatment -- pregnancy; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa362
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.